The Federal Ministry of Education and Research (German: Bundesministerium für Bildung und Forschung, BMBF), supports innovative projects and ideas in research through targeted funding programmes. Direct project funding is allocated to concrete areas of research and is implemented within the framework of specific programmes. These promote basic technologies which push forward developments in key fields of application and thus serve as a force for growth in many industrial sectors. They support German industrial companies including small and medium-sized enterprises (SMEs) as well as universities, institutions of higher education and other R&D institutions and are generally open for international cooperation.
The 'European and Developing Countries Clinical Trials Partnership' aims to support collaborative research that accelerates the clinical development of new or improved interventions to prevent or treat HIV/AIDS, tuberculosis, malaria, and other poverty-related infectious diseases, including neglected infectious diseases and emerging or re-emerging infectious diseases, prevalent in sub-Saharan Africa. The current second EDCTP programme is supported under Horizon 2020, the European Union's Framework Programme for Research & Innovation, and executed through partnerships between European and African institutions and researchers in collaboration with the pharmaceutical industry and like-minded organisations.
EIT Health was established in 2015 as a ‘knowledge and innovation community’ (KIC) of the European Institute of Innovation and Technology (EIT). The EIT comprises various KICs who focus on a different sector or area of innovation. In the case of EIT Health it is ‘health and aging.’ The idea behind the EIT KICs is that innovation flourishes best when the right people are brought together to share expertise. EIT Health provides funding to interdisciplinary groups of experts from business, research, and education, aiming to create an optimal innovation environment.
Horizon 2020 was the Eighth Framework Programme funding Research, Technological Development, and Innovation‘, implemented by the European Commission. It provided nearly €80 billion of funding over seven years (2014 to 2020) to research and innovation projects through open and competitive calls for proposals. It was organised around societal challenges and open to participation from around the globe.
Horizon Europe is the European Union's Ninth Research and Innovation Framework Programme, which will run between 2021 and 2024. The programme is the world's largest funding programme of its kind with a €95.5 billion budget. Horizon Europe is, just like its predecessor Horizon 2020, made up of three pillars: open science, global challenges, and industrial competitiveness.
New goals in Horizon Europe include creating a stronger impact through mission-orientation and a more active engagement of society through better dissemination and exploitation of R&I results. Another new feature in Horizon Europe is the institutionalisation of the European Innovation Council (EIC).
Operating across the UK with a combined budget of more than £7 billion, UK Research and Innovation (UKRI) brings together the seven UK research councils, Innovate UK, and Research England. UKRI works in partnership with universities, research organisations, businesses, charities, and the UK government to create the best possible environment for research and innovation to flourish. The 'Medical Research Council‘ MRC supports medical research, spending around £800 million each year by providing research grants and career awards to scientists. Funding opportunities are either researcher-led or MRC strategic. Researcher-led proposals are reviewed at board and panel meetings, with funding available for any science area relevant to the MRC, and provide support on a range of scales across career stages, from fundamental to translational research.
The National Institutes of Health (NIH) is the United States government's primary agency responsible for biomedical and public health research. The NIH conducts its own scientific research through its Intramural Research Program and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program. Of that, a certain percentage must be granted to small businesses under the SBIR/STTR Program. Main areas of funding include clinical research, genetics, prevention, cancer, and biotechnology.